FORTITUDE study met primary and key secondary endpoints of reduction in KHDC1L and creatine kinase levels, with safety profile consistent with previous results Del-brax indicates potential to become ...
Novartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Congress 2026
About Novartis Immunology At Novartis, we’re advancing bold science with the goal of bringing relief and a renewed sense of hope to people living with autoimmune diseases. Building on our legacy of ...
Basel, May 17, 2026 – Novartis today announced new data from PSMAddition demonstrating improved prostate-specific antigen (PSA) responses with Pluvicto ® (lutetium (177Lu) vipivotide tetraxetan) ...
studies were published in Nature Medicine. Following the CHMP’s recommendation for approval, the European Commission (EC) is expected to issue a final decision within approximately two months. About ...
Novartis has announced new long-term Social Impact & Sustainability (SI&S) targets and goals, reinforcing our commitment to go beyond breakthroughs to maximize the impact of our medicines to support ...
～2歳未満を対象としたゾルゲンスマ ® 点滴静注に次ぐ、SMAの新たな治療選択肢～ ノバルティス ファーマ株式会社（本社：東京都港区、代表取締役社長：ジョンポール・プリシーノ、以下 ...
Proposed acquisition supports the Novartis oncology strategy in hormone receptor positive, human epidermal growth factor receptor two-negative (HR+/HER2-) breast cancer The lead asset, SNV4818, ...
Cosentyx is the only IL-17A inhibitor approved for this population, and the first differentiated mechanism in nearly a decade1-3 HS often emerges around puberty, underscoring importance of early ...
A Q&A with Jake Haling, Head of Oncology Drug Discovery in San Diego, on induced proximity and how it could open new paths to treat cancer. At Novartis Biomedical Research, oncology teams around the ...
. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result ...
Site to serve patients in Southern US and add network capacity as RLT expands into earlier treatment lines and additional tumor types Company broke ground on 4 new manufacturing and R&D facilities, ...
Designation based on clinical evidence supporting potential of ianalumab in Sjögren’s disease, including phase III trials1 Distinction expedites development and review of treatments for serious ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results